Home » Author Archives: Catherine Skari (page 4)

Author Archives: Catherine Skari

FDA and EMA Collaborate to Facilitate COVID-19 Vaccine Development

  Global regulators have published a report today presenting the outcomes of a workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). This report was the outcome of March 18th first global regulators meeting, chaired jointly by the the ...

Read More »

A Useful Health & Nutrition Short Guide for the COVID-19 Pandemic by TIF

The coronavirus presents many uncertainties, and none of us can completely eliminate the risk of getting infected with COVID-19. Nevertheless, one thing we can do is eat as healthy as possible! In addition to the well-known personal hygiene and preventive measures against the new coronavirus (COVID-19), we can also follow ...

Read More »

AABB’s Develops Toolkit with Information Regarding Blood Donation & the COVID-19 Outbreak

  As the new coronavirus continues to spread affecting an increasing number of countries around the globe and in response to FDA’s Important Information for Blood Establishments Regarding the Novel Coronavirus (COVID-19) Outbreak (FDA Communication), AABB has recently developed a useful toolkit with important information about coronavirus and blood donation, in ...

Read More »


  “My family is from Greece originally but I was born and grew up in Wales, a country which even today has very few thalassaemia patients. When I was born 38 years ago, nobody – including my family – had any idea what was in store. I was eventually diagnosed ...

Read More »

FT-4202 Granted FDA Fast Track, Rare Pediatric Disease Designations for SCD

FT-4202, a potential disease-modifying oral treatment for sickle cell disease being developed by Forma Therapeutics, has been given fast track and rare pediatric disease designations by the U.S. Food and Drug Administration (FDA). A fast track status is meant to accelerate the development and review of the treatment, facilitating discussions with the FDA and enabling the therapy ...

Read More »